

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden	
hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Topspin Fund L.P.</u> <hr/> (Last) (First) (Middle) 3 EXPRESSWAY PLAZA <hr/> (Street) ROSLYN NY 11577 <hr/> (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>Oric Pharmaceuticals, Inc. [ ORIC ]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) 11/04/2020	
4. If Amendment, Date of Original Filed (Month/Day/Year)		

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	11/04/2020		S		2,268,750	D	(2)	1,100,446 <sup>(1)(2)(3)</sup>	I	See Footnote <sup>(1)</sup>

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V		Date Exercisable	Expiration Date					

1. Name and Address of Reporting Person\*  
Topspin Fund L.P.  


---

 (Last) (First) (Middle)  
 3 EXPRESSWAY PLAZA  


---

 (Street)  
 ROSLYN NY 11577  


---

 (City) (State) (Zip)

1. Name and Address of Reporting Person\*  
Topspin Biotech Fund II, L.P.  


---

 (Last) (First) (Middle)  
 3 EXPRESSWAY PLAZA  


---

 (Street)  
 ROSLYN NY 11577  


---

 (City) (State) (Zip)

1. Name and Address of Reporting Person\*  
LG Management, LLC  


---

 (Last) (First) (Middle)  
 3 EXPRESSWAY PLAZA

(Street)  
ROSLYN  
HEIGHTS NY 11577

---

(City) (State) (Zip)

1. Name and Address of Reporting Person\*

GUTHART LEO

(Last) (First) (Middle)  
3 EXPRESSWAY PLAZA

(Street)  
ROSLYN  
HEIGHTS NY 11577

(City) (State) (Zip)

**Explanation of Responses:**

1. Consists of (1) 1,043,874 shares held of record by Topspin Fund, LP; and (2) 56,572 shares owned by Leo A Guthart, individually. Each of Topspin Fund, LP and Leo A. Guthart disclaims beneficial ownership of the shares held of record by the other.

2. On November 4, 2020, Topspin Biotech Fund II, L.P. distributed the 2,268,750 shares owned by it as follows: (1) 2,155,607 shares were distributed in-kind to its limited partners; and (2) 113,143 were distributed at the direction of LG Management, LLC, the general partner of Topspin Biotech Fund II, L.P., as follows: (a) 56,572 were distributed to Leo A. Guthart, the managing member of LG Management, LLC; and (b) an aggregate of 56,571 were distributed to two third-parties. The 113,143 shares distributed at the direction of LG Management, LLC were shares to which it was entitled in its capacity as general partner of Topspin Biotech Fund II, L.P.

3. 1,043,874 of such shares are held directly by Topspin Fund L.P. LG Management, LLC, the general partner of Topspin Fund L.P., may be deemed to have voting and dispositive power with respect to the shares. Leo A. Guthart, the managing member of LG Management, LLC, may also be deemed to have voting and dispositive power with respect to the shares. Each of LG Management, LLC and Leo A. Guthart disclaims beneficial ownership of the shares, except to the extent of their respective indirect pecuniary interests in such shares.

TOPSPIN FUND L.P., /s/ Leo  
A. Guthart, Managing  
Member of the General  
Partner 11/05/2020

TOPSPIN BIOTECH FUND  
II, L.P., /s/ Leo A. Guthart,  
Managing Member of the  
General Partner 11/05/2020

LG MANAGEMENT, LLC,  
/s/ Leo A. Guthart, Managing  
Member 11/05/2020

/s/ Leo A. Guthart 11/05/2020

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.